Tharimmune, Inc. — Director's Dealing 2023

Jan 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2023-01-01

Reporting Person: MILBY RANDY (Director, Chief Executive Officer, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-01	Options (right to purchase)	$0.39	A	621795	Acquired	2033-01-01	Common stock (621795)	Direct

Footnotes

F1: The options were issued pursuant to the Issuer's 2019 Stock Incentive Plan and vested in full upon grant.